Better outcomes in T2DM with no delay in tx intensification
(HealthDay)—For patients with type 2 diabetes, not delaying intensification of oral antidiabetic drugs (OADs) is associated with greater reductions in hemoglobin A1c (HbA1c), and with reduced risks of cardiovascular events ...
Mar 11, 2017
0
0